Wednesday 17 November 2021, SINGAPORE
Labcorp (NYSE: LH), a leading global life sciences company, announced the expansion of its global offerings and its footprint in the Asia-Pacific (APAC) region with the opening of a new, integrated bioanalytical laboratory in Singapore.
The laboratory features new capabilities that enhance the substantial array of bioanalytical services currently offered through Labcorp Drug Development, allowing the company to meet increased demand from pharmaceutical and biotechnology companies.
“Singapore serves as a strategic location from which Labcorp can increase accessibility by offering regional and international clients comprehensive support for their bioanalytical studies,” said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. “With this expansion, the company is advancing its position as a life science leader in the region and across the globe. The all-in-one Singapore laboratory offers clients faster turnaround times for data in early phase trials occurring in the APAC region.”
The integrated bioanalytical laboratory will be co-located with Labcorp’s Central Laboratory Services and Clinical Development and Commercialization Services segments, bolstering the company’s laboratory network in APAC. By expanding its bioanalytical capabilities in Singapore, Labcorp advances its regulated and non-regulated services and further supports the development of small and large molecule studies. The new, integrated laboratory will also offer Good Laboratory Practice (GLP)- and Good Clinical Practice (GCP)-compliant bioanalysis, liquid chromatography-mass spectrometry, and immunochemistry platforms, as well as clinical biomarker analytical services.
Labcorp hosted an opening ceremony for the laboratory on Wednesday, Nov. 10. Gan Kim Yong, Singapore’s minister for trade and industry, and Dr. Kirchgraber officiated the ceremony. The event also featured a keynote presentation, a virtual lab tour, and scientific sessions from an impressive line-up of Labcorp Drug Development scientists.
In line with Singapore’s plans for Emerging Stronger, this expansion will strengthen the nation’s position as an end-to-end hub for medical technology product development under the Alliance for Action approach. It will also enable comprehensive, end-to-end in vitro diagnostic solutions development and commercialization.
( original url )
back to News